Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coumarin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43892   clinical trials with a EudraCT protocol, of which   7299   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Coumarin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-016992-31 Sponsor Protocol Number: COU-001A Start Date*: 2010-03-19
    Sponsor Name:Democritus Universityof Thrace Medical School [...]
    1. Democritus Universityof Thrace Medical School
    2. University Utrecht
    3. Fundacion Marques de Valdecilla
    Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial
    Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with phenprocoumon.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    12.1 10012107 Deep venous thrombosis NOS LLT
    12.1 10037377 Pulmonary embolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016993-34 Sponsor Protocol Number: COU-001W Start Date*: 2010-09-02
    Sponsor Name:Uppsala University Hospital
    Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial
    Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with warfarin.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    14.1 10047065 - Vascular disorders 10012107 Deep venous thrombosis NOS LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016994-13 Sponsor Protocol Number: COU-001P Start Date*: 2010-03-19
    Sponsor Name:University Utrecht [...]
    1. University Utrecht
    2. Prof. Dr. R Marre, University Hospital Ulm
    3. Elisabethinen Hospital Linz
    Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial
    Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with phenprocoumon.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003658 Atrial fibrillation LLT
    12.0 10012107 Deep venous thrombosis NOS LLT
    12.0 10037377 Pulmonary embolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000382-19 Sponsor Protocol Number: BE1116_3001 Start Date*: 2005-09-15
    Sponsor Name:ZLB Behring GmbH
    Full Title: Efficacy and tolerance of BERIPLEX® P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation
    Medical condition: Acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation requiring an immediate reversal of anticoagulant effect (i.e. emergency surgery or acute bleeding).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000534 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004595-13 Sponsor Protocol Number: BAY59-7939/11630 Start Date*: 2009-03-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939...
    Medical condition: Prevention of Stroke and Non-CNS Systemic Embolism in Non-Valvular Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Completed) DK (Completed) BE (Completed) HU (Completed) SE (Completed) LT (Completed) GB (Completed) CZ (Completed) FR (Completed) BG (Completed) GR (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005395-27 Sponsor Protocol Number: 4705 Start Date*: 2009-01-27
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Inter-individual variability in response to warfarin in children: Analysis of environmental and pharmacogenetic factors
    Medical condition: The study population will consist of children (0-18 years of age) who are anticoagulated with warfarin.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051445 Foetal warfarin syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001401-42 Sponsor Protocol Number: Erlosora-1 Start Date*: 2008-12-03
    Sponsor Name:Medizinische Universität Wien, Univ. KlM III, Klinische Abt. f. Gastroenterologie/Hepatologie
    Full Title: Combination of Erlotonib plus Sorafenib in Patients with unresectable Hepatocellular Carcinoma; a randomized placebo controlled Phase II pilot trial.
    Medical condition: Unresectable Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008259-41 Sponsor Protocol Number: OZR-2008-20 Start Date*: 2009-03-30
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ...
    Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005083-28 Sponsor Protocol Number: BAY 43-9006 / 12782 Start Date*: 2008-02-27
    Sponsor Name:Bayer Healthcare AG, Leverkusen
    Full Title: Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne...
    Medical condition: Carcinoma metastásico de células renales (Advanced renal cell cancer.)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001090-15 Sponsor Protocol Number: MADONNA Start Date*: 2008-09-10
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.
    Medical condition: metastatic HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018849-59 Sponsor Protocol Number: GMIHO-008/2009_AG56 Start Date*: 2011-05-10
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer
    Medical condition: Platinum-sensitive recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019250-41 Sponsor Protocol Number: 220901 Start Date*: 2010-05-27
    Sponsor Name:Baxter Innovations GmbH
    Full Title: AN INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, OPEN-LABEL, NON-RANDOMISED, UNCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROTHROMPLEX TOTAL IN ORAL ANTICOAGULANT REVERSAL IN PATIENTS WITH A...
    Medical condition: Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) due to oral anticoagulant therapy with Vitamin K antagonists
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037045 Prothrombin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006611-23 Sponsor Protocol Number: MO21609 Start Date*: 2008-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) NL (Completed) PT (Completed) GB (Completed) FI (Completed) SE (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003793-26 Sponsor Protocol Number: 3066K1-3311-WW Start Date*: 2008-05-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
    Medical condition: First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) BE (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003972-23 Sponsor Protocol Number: hcc1 Start Date*: 2009-01-09
    Sponsor Name:LUMC
    Full Title: Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment
    Medical condition: The primary objective of this study is to determine the efficacy of the combination of everolimus and capecitabine in a group of patients with metastatic or locally advanced HCC. In addition, to in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    9.1 10019829 Hepatocellular carcinoma recurrent LLT
    9.1 10008452 Chemotherapy multiple agents systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004961-42 Sponsor Protocol Number: PET_imaging_of_kinase_inhibitors Start Date*: 2013-05-23
    Sponsor Name:Medical Oncology, VUmc
    Full Title: Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies
    Medical condition: Advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005545-20 Sponsor Protocol Number: IJBNMDOCASTOR Start Date*: 2014-12-23
    Sponsor Name:Institut Jules Bordet
    Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b
    Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000678-19 Sponsor Protocol Number: MCL2008-01 Start Date*: 2010-08-05
    Sponsor Name:Klinikum der Universität München, Klinikum Großhadern
    Full Title: Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network
    Medical condition: patients with relapsed or refractory mantle cell lymphoma after or not eligible for myeloablative treatment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10026800 Mantle cell lymphoma recurrent PT
    12.0 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004968-40 Sponsor Protocol Number: TUD-SORAML-034 Start Date*: 2009-02-20
    Sponsor Name:Technische Universität Dresden
    Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Medical condition: Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10001941 AML LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018850-11 Sponsor Protocol Number: MHH_CCA_AG54 Start Date*: 2011-04-15
    Sponsor Name:Medizinische Hochschule Hannover (MHH)
    Full Title: Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study
    Medical condition: cholangiocarcinoma / gall bladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 29 16:18:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA